Upstate Active Clinical Trials
Study Title:A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
What is the purpose of the study?To assess the impact on progression-free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment after induction therapy with lenalidomide, ixazomib, dexamethasone, and daratumumab
Upstate Institutional Review Board (IRB) Number:1846245
Patient Age Group:Adults
Principal Investigator:Krishna B Ghimire, MD
What is involved if I participate?
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
Who can I contact for more information?
Name: Hardikkumar Panchal, MPA, MS